|
Molecular biomarkers
|
High-grade serous carcinoma
|
Clear cell carcinoma
|
P
e value
|
|---|
| |
Cases (%)
|
P(OS)
|
P(PFS)
|
Cases (%)
|
P(OS)
|
P(PFS)
| |
|---|
|
EGFR
|
113(100)
|
0.017
|
0.042
|
92(100)
|
0.012
|
0.267
|
0.195
|
|
Negative
|
82(72.6)
| | |
59(64.1)
| | | |
|
Positive
|
31(27.4)
| | |
33(35.9)
| | | |
|
HER2
|
113(100)
|
0.938
|
0.475
|
95(100)
|
0.001
|
0.200
|
0.006
|
|
Negative
|
110(97.3)
| | |
83(87.4)
| | | |
|
Positive
|
3(2.7)
| | |
12(12.6)
| | | |
|
PTEN
|
113(100)
|
0.323
|
0.397
|
93(100)
|
0.160
|
0.061
|
0.716
|
|
Negative
|
99(87.6)
| | |
83(89.2)
| | | |
|
Positive
|
14(12.4)
| | |
10(10.8)
| | | |
|
AURKA
|
113(100)
|
0.006
|
0.382
|
95(100)
|
0.022
|
0.035
|
0.582
|
|
Negative
|
72(63.7)
| | |
57(60.0)
| | | |
|
Positive
|
41(36.3)
| | |
38(40.0)
| | | |
|
BRCA1
|
113(100)
|
0.017
|
0.032
|
92(100)
|
0.823
|
0.424
|
0.007
|
|
Negative
|
82(72.6)
| | |
50(54.3)
| | | |
|
Positive
|
31(27.4)
| | |
42(45.7)
| | | |
|
BRCA2
|
113(100)
|
0.743
|
0.500
|
94(100)
|
0.466
|
0.929
|
0.054
|
|
Negative
|
101(89.4)
| | |
75(79.8)
| | | |
|
Positive
|
12(10.6)
| | |
19(20.2)
| | | |
|
PD-L1
|
113(100)
|
0.037
|
0.159
|
95(100)
|
0.773
|
0.425
|
0.064
|
|
Negative
|
99(88.4)
| | |
75(78.9)
| | | |
|
Positive
|
13(11.6)
| | |
20 (21.1)
| | | |
- A total of 113 cases of HGSC and 96 cases of CCC have both primary tumor immunohistochemistry results and survival information. However, the total number for each antibody does not add to up 96 in CCC group
-
aChi-squared tests were performed for the difference of positive rates between HGSC and CCC groups
- Bold value denotes P with statistical significance
